Literature DB >> 27426304

The evolution of P2X7 antagonists with a focus on CNS indications.

Jason C Rech1, Anindya Bhattacharya1, Michael A Letavic1, Brad M Savall1.   

Abstract

The P2X7 receptor is an ATP-gated nonselective cation channel that has been linked to a number of inflammatory diseases. Activation of the P2X7 receptor by elevated levels of ATP results in the release of proinflammatory cytokines and elevated levels of these cytokines has been associated with a variety of disease states. A number of research groups in both industry and academia have explored the identification of P2X7R antagonists as therapeutic agents. Much of this early effort focused on the treatment of diseases related to peripheral inflammation and resulted in several clinical candidates, none of which were advanced to market. The emerging role of the P2X7 receptor in neuroinflammation and related diseases has resulted in a shift in medicinal chemistry efforts toward the development of centrally penetrant antagonists. This review will highlight the biology supporting the role of P2X7 in diseases related to neuroinflammation and review the recent medicinal chemistry efforts to identify centrally penetrant antagonists.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Brain penetrant; Heteroaromatic; Heterocyclic; IL-1β; Neuroinflammation; P2X7; Purinergic

Mesh:

Substances:

Year:  2016        PMID: 27426304     DOI: 10.1016/j.bmcl.2016.06.048

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  19 in total

Review 1.  Purinergic drug targets for gastrointestinal disorders.

Authors:  Geoffrey Burnstock; Kenneth A Jacobson; Fievos L Christofi
Journal:  Curr Opin Pharmacol       Date:  2017-11-14       Impact factor: 5.547

Review 2.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

3.  Arylboronic acids inhibit P2X7 receptor function and the acute inflammatory response.

Authors:  Robson Xavier Faria; Noemi de Jesus Hiller; Juliana Pimenta Salles; Jackson Antonio Lamounier Camargos Resende; Roberta Tosta Diogo; Natalia Lidmar von Ranke; Murilo Lamim Bello; Carlos Rangel Rodrigues; Helena Carla Castro; Daniela de Luna Martins
Journal:  J Bioenerg Biomembr       Date:  2019-06-29       Impact factor: 2.945

4.  Agonists, Antagonists, and Modulators of P2X7 Receptors.

Authors:  Christa E Müller; Vigneshwaran Namasivayam
Journal:  Methods Mol Biol       Date:  2022

5.  Müller Cell-Microglia Cross Talk Drives Neuroinflammation in Diabetic Retinopathy.

Authors:  Steven F Abcouwer
Journal:  Diabetes       Date:  2017-02       Impact factor: 9.461

Review 6.  The Metabotropic Purinergic P2Y Receptor Family as Novel Drug Target in Epilepsy.

Authors:  Mariana Alves; Edward Beamer; Tobias Engel
Journal:  Front Pharmacol       Date:  2018-03-07       Impact factor: 5.810

Review 7.  The ATP-Gated P2X7 Receptor As a Target for the Treatment of Drug-Resistant Epilepsy.

Authors:  Edward Beamer; Wolfgang Fischer; Tobias Engel
Journal:  Front Neurosci       Date:  2017-02-02       Impact factor: 4.677

Review 8.  The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression.

Authors:  Geoffrey Burnstock; Gillian E Knight
Journal:  Purinergic Signal       Date:  2017-11-21       Impact factor: 3.765

Review 9.  Update of P2X receptor properties and their pharmacology: IUPHAR Review 30.

Authors:  Peter Illes; Christa E Müller; Kenneth A Jacobson; Thomas Grutter; Annette Nicke; Samuel J Fountain; Charles Kennedy; Günther Schmalzing; Michael F Jarvis; Stanko S Stojilkovic; Brian F King; Francesco Di Virgilio
Journal:  Br J Pharmacol       Date:  2020-12-21       Impact factor: 9.473

Review 10.  P2X7 Receptor-Associated Programmed Cell Death in the Pathophysiology of Hemorrhagic Stroke.

Authors:  Hengli Zhao; Yujie Chen; Hua Feng
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.